COVID-19 Drug Treatment* SARS-CoV-2 / drug effects* Tetracyclines / therapeutic use* Anti-Bacterial Agents
2020 May;40(5):487-488
Therefore, the zinc-chelating properties of TCs may aid in inhibiting COVID
Expert opinion: The concomitant use of dexamethasone and one of the tetracyclines among severe COVID-19 patients offers several advantages in terms of additive
Methods: We performed a multicenter prospective observational study that enrolled COVID-19 patients visited with teledermatology and undergoing TetraC
Tetracycline’s immunomodulatory and anti-inflammatory properties may be of greater relevance for protection against COVID-19 severe pathology than their potential antiviral activity (Figure 2(b-d))
1002/phar
g
Introduction: The global coronavirus disease-2019 (COVID-19) pandemic has posed a critical challenge to the research community as well as to the healthcare systems
and tetracyclines) in 71 countries during March 2020–May 2022 from the IQVIA MIDAS® database
Tetracycline treatment within a year before ARDS diagnosis was associated with 75% reduced likelihood for mechanical ventilation during
In the present study, we Among COVID-19 patients receiving ventilator support, a multidrug-resistant A
It was often trialed in conjunction with hydroxychloroquine
To clarify the clinical course and prognosis, we followed a
tetracycline, doxycycline, and minocycline) can chelate zinc (Zn) compounds on matrix metalloproteinases (MMPs)
According to the World Health Organization (WHO), antibiotics are not effective in the treatment of COVID-19, which the new coronavirus causes